Sahajanand Medical Technologies' initial public offering (IPO) has been subscribed 2.05 times as of the third and final day of bidding. This means that investors have placed bids for more than twice the number of shares available. The IPO is an offer for sale (OFS) of up to 1.38 crore equity shares by existing shareholders, with no fresh shares being issued by the company.
- The IPO received bids for 1,99,62,320 shares against 97,50,482 shares on offer.
- Qualified Institutional Buyers (QIBs) subscribed 1.59 times.
- Retail investors subscribed 1.65 times.
- Non-institutional investors subscribed 3.79 times.
- The IPO size is ₹475.48 crore, with a price band of ₹327 to ₹344 per share.
- Allotment is expected on October 21, and listing on the stock market will occur on October 23.
What is Sahajanand Medical Technologies and its IPO structure?
Sahajanand Medical Technologies is a company specializing in the development and manufacturing of Class III and Class C/D medical devices, focusing on vascular intervention and structural heart products. It is known for producing cardiac stents and other advanced medical devices.
The IPO is a pure offer for sale, meaning existing shareholders are selling their shares, and the company itself is not issuing any new shares. As a result, the company will not receive any proceeds from the IPO. Instead, the funds raised will go directly to the selling shareholders.
How has the IPO been received by different investor categories?
The IPO has attracted strong interest from various investor groups. Qualified Institutional Buyers (QIBs), which include mutual funds and insurance companies, subscribed 1.59 times the shares allocated to them. Retail investors, who are individual investors, subscribed 1.65 times. Non-institutional investors, which include high-net-worth individuals and other entities, showed the highest interest with 3.79 times subscription.
What are the key dates and details for investors?
The price band for the IPO was set between ₹327 and ₹344 per share. Each lot consists of 43 shares, making the minimum investment amount approximately ₹14,061 at the upper price band.
The basis of allotment, which determines how shares will be allocated to investors, is expected to be finalized on October 21. Following allotment, the shares will be listed on the stock exchange on October 23, allowing investors to trade the shares publicly.
What benefits does the company expect from listing?
Although the company will not raise new funds through this IPO, it expects that listing its shares on the stock exchange will enhance its visibility and brand recognition. Additionally, listing will provide liquidity to existing shareholders, allowing them to buy and sell shares more easily in the public market.
According to the company's red herring prospectus, the public market listing will also provide a platform for equity shares in India, which can be beneficial for future growth and investor confidence.
In summary, Sahajanand Medical Technologies' IPO has seen strong subscription levels across all investor categories. With allotment and listing dates approaching, investors are keenly awaiting the opportunity to participate in the company's public market journey.
